Eli Lilly CEO: The Weight-Loss Drug Revolution, AI in Pharma, and Innovation
In Good Company with Nicolai Tangen
Intro
This chapter explores the advancements in weight-reducing medications, particularly GLP-1 agonists, and their effectiveness in treating obesity and other health issues. The discussion highlights the evolution of these drugs, from their inception to innovative formulations, and their significant impact on metabolic and neurological health.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
